{"prompt": "['CONFIDENTIAL', 'Verrica Pharmaceuticals Inc.', 'VP-102', 'Clinical Protocol: VP-102-103', 'TABLE OF CONTENTS (continued)', 'Page', '8.0', 'REFERENCES', '65', '8.1', 'UNPUBLISHED MANUSCRIPT', '67', 'Page 14']['CONFIDENTIAL', 'Verrica Pharmaceuticals Inc.', 'VP-102', 'Clinical Protocol: VP-102-103', 'LIST OF TABLES', 'Page', 'Study Schedule of Assessments and Procedures', '10', 'Table 1.', 'Classification of AEs by Intensity', '50', 'Table 2.', 'Assessment of Causality of AEs', '51', 'Table 3.', 'Timeline for Reporting SAEs', '52', 'LIST OF FIGURES', 'Page', 'Figure 1.', 'Clinical Trial Labeling of Study Drug Applicator', '35', 'Figure 2.', 'Clinical Trial Labeling of Study Drug Tyvek Pouch', '35', 'Page 15']['CONFIDENTIAL', 'Verrica Pharmaceuticals Inc.', 'VP-102', 'Clinical Protocol: VP-102-103', 'LIST OF ABBREVIATIONS', 'AE', 'adverse event', 'AEs', 'adverse events', 'CDLQI', \"children's dermatology life quality index\", 'CRF', 'case report form', 'EOS', 'end of study', 'EOT', 'end of treatment', 'EDC', 'electronic data capture', 'FDA', 'Food and Drug Administration', 'ICF', 'informed consent form', 'ICH', 'International Council for Harmonization', 'ID', 'identification', 'IRB', 'institutional review board', 'ml', 'milliliters', 'Molluscum', 'molluscum contagiosum', 'ng', 'nanograms', 'LSR', 'local skin reaction', 'SAE', 'serious adverse event', 'SOP', 'standard operating procedure', 'PERIT', 'patient evaluation of response to investigational treatment', 'T24', 'human bladder carcinoma cells', 'TSGH 8301', 'human urinary bladder carcinoma cell line', 'VP-102', 'Verrica Pharmaceuticals-102 (0.7% w/v cantharidin)', 'w/v', 'weight/volume', 'Page 16']\n\n###\n\n", "completion": "END"}